Using an antigen presentation pathway that is widely conserved in Gram-positive bacteria, SIGA scientists are able to engineer commensal bacteria to present a heterologous antigen of choice on their external surface. Vaccines are being developed for chlamydia, strep throat, neisseria, and cancer. Drug resistance - SIGA's antibiotic program targets the growing problem of drug resistant bacteria.
Programs are underway in defense application, protein production, and animal health.